N. Beveridge

Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populations

R. Koup, D. Douek, D. Ambrozak, 2007, European journal of immunology.

Establishment of an Aerosol Challenge Model of Tuberculosis in Rhesus Macaques and an Evaluation of Endpoints for Vaccine Testing

Adrian V. S. Hill, Fergus V. Gleeson, Sally Sharpe, 2010, Clinical and Vaccine Immunology.

Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining

H. Dockrell, H. McShane, Steven G. Smith, 2010, BMC Immunology.

Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A

H. McShane, A. Hill, H. Fletcher, 2011, PloS one.

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

R. Davies, F. Gleeson, H. McShane, 2009, American journal of respiratory and critical care medicine.

A comparison of IFNgamma detection methods used in tuberculosis vaccine trials.

H. Dockrell, T. Scriba, W. Hanekom, 2008, Tuberculosis.

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials

H. McShane, A. Hill, H. Fletcher, 2007, PloS one.

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults

A. Winston, R. Koup, D. Douek, 2011, BMJ Open.